ArticleClinical and diagnostic laboratory immunology2001
Effect of intranasal administration of Lactobacillus casei Shirota on influenza virus infection of upper respiratory tract in mice.
Article in Clinical and diagnostic laboratory immunology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02687503 (Impact of Probiotic Use on Immune Cell Function in Children), which is not on this map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Probiotic Use on Immune Cell Function in Children
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- The Intriguing Connection Between the Gut and Lung Microbiomes.Pathogens (Basel, Switzerland) · 2024Pooled it
- Oxygen-driven nebulization of Clostridium butyricum prevents drug-resistant bacterial pneumonia.Applied microbiology and biotechnology · 2026Trial
- Microbiome TherapeuticJournal of microbiology and biotechnology · 2025Article
- Causal relationship between gut microbiota and pneumonia: a Mendelian randomization and retrospective case-control study.BMC pulmonary medicine · 2025Article
- Harnessing the Farm Effect: Microbial Products for the Treatment and Prevention of Asthma Throughout Life.Immunological reviews · 2025Review
- Article
- Review
- The Effect ofMicroorganisms · 2023Article
- Gut Microbiota and Respiratory Infections: Insights from Mendelian Randomization.Microorganisms · 2023Article
- The Potential of Probiotics as Ingestible Adjuvants and Immune Modulators for Antiviral Immunity and Management of SARS-CoV-2 Infection and COVID-19.Pathogens (Basel, Switzerland) · 2023Review
- Lung Microbiota: Its Relationship to Respiratory System Diseases and Approaches for Lung-Targeted Probiotic Bacteria Delivery.Molecular pharmaceutics · 2023Review
- The beneficial effects of spraying of probiotic Bacillus and Lactobacillus bacteria on broiler chickens experimentally infected with avian influenza virus H9N2.Poultry science · 2023Article
- Article
- Malnutrition and Dietary Habits Alter the Immune System Which May Consequently Influence SARS-CoV-2 Virulence: A Review.International journal of molecular sciences · 2022Review
- Review
- Gut and lung microbiome profiles in pregnant mice.Frontiers in microbiology · 2022Article
- The role of respiratory microbiota in the protection against viral diseases: respiratory commensal bacteria as next-generation probiotics for COVID-19.Bioscience of microbiota, food and health · 2022Review
- The Beneficial Role of ProbioticFrontiers in immunology · 2022Review
- Modulated Gut Microbiota for Potential COVID-19 Prevention and Treatment.Frontiers in medicine · 2022Review
- Cross-talk between immune system and microbiota in COVID-19.Expert review of gastroenterology & hepatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In mice administered Lactobacillus casei strain Shirota (LcS) intranasally, potent induction of interleukin 12, gamma interferon, and tumor necrosis factor alpha, which play a very important role in excluding influenza virus (IFV), was evident in mediastinal lymph node cells. In this model of upper respiratory IFV infection, the titers of virus in the nasal wash of mice inoculated with 200 microg of LcS for three consecutive days (LcS 200 group) before infection were significantly (P < 0.01) lower than those of mice not inoculated with LcS (control group) (10(0.9 +/- 0.6) versus 10(2.1 +/- 1.0)). The IFV titer was decreased to about 1/10 of the control level. Using this infection model with modifications, we investigated whether the survival rate of mice was increased by intranasal administration of LcS. The survival rate of the mice in the LcS 200 group was significantly (P < 0.05) greater than that of the mice in the control group (69% versus 15%). It seems that the decrease in the titer of virus in the upper respiratory tract to 1/10 of the control level was important in preventing death. These findings suggest that intranasal administration of LcS enhances cellular immunity in the respiratory tract and protects against influenza virus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.